Recently, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax” or the “Company”) successfully held the Kick-off Meeting & Investigator Training for Phase I Clinical Trials of Trivalent & Quadrivalent Influenza Virus Split Vaccines (MDCK Cells) in Xiangyun County, Xiangyun County, Dali Bai Autonomous Prefecture, Yunnan Province, marking new progress for the Company in the field of viral vaccines.

This meeting was hosted by the Yunnan Provincial Center for Disease Control and Prevention. Relevant leaders from the Yunnan Provincial Center for Disease Control and Prevention, the People’s Government of Xiangyun County, the Xiangyun County Health Bureau, and the Xiangyun County Center for Disease Control and Prevention attended the meeting and delivered speeches. Mr. Fan Shaowen, Chairman and General Manager of Olymvax, and Mr. Zhan Tao, Vice President of Chengdu Bonacius Pharmaceutical Technology Co., Ltd. (CRO), delivered speeches. All parties fully affirmed the innovativeness, safety advantages, quality advantages and market advantages of the Company’s trivalent and quadrivalent influenza virus split vaccines (MDCK cells), expressed support and expectations for the upcoming clinical trials, and put forward high standards and strict requirements for the progress and quality of the clinical trial project.

Subsequently, in the training session, relevant experts from the Yunnan Provincial Center for Disease Control and Prevention gave in-depth training on GCP, relevant regulations on vaccine clinical trials, and the protection of subjects’ rights and interests in vaccine clinical trials. The meeting also provided detailed training on the clinical trial protocol and operational procedures to ensure that all participants had a full understanding of the norms and requirements of clinical trials.

Olymvax focuses on the R&D, production and commercialization of human vaccines, has established an orderly product pipeline, and possesses outstanding capabilities in the transformation of R&D achievements. Influenza series vaccines are important achievements of the Company’s expansion from bacterial vaccines to viral vaccines. The Company’s cell-based influenza series vaccines can achieve higher production yields, more stable product quality and lower production costs through large-scale cultivation in bioreactors. Foreign manufacturers such as CSL have launched cell-based influenza vaccines, while no cell-based influenza vaccine is available in China at present. The Company will continue to advance clinical trial projects of influenza series vaccines, strive to complete relevant research at an early date, so as to further extend the Company’s R&D pipeline and enhance its market competitiveness.